$KRRO News

Korro Bio Announces Addition Of KRRO-111 For Potential Treatment Of AATD To Pipeline Of Therapeutic Programs In Development

HC Wainwright & Co. Maintains Buy on Korro Bio, Lowers Price Target to $15

Citigroup Initiates Coverage On Korro Bio with Buy Rating, Announces Price Target of $21

Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update

Korro Bio Q1 EPS $(1.69) Beats $(2.17) Estimate

Korro to Participate in Upcoming Investor Conferences

What Makes Korro Bio, Inc. (KRRO) a New Buy Stock

Korro Bio Presents Oral, Poster Presentations Of Data From Its Oligonucleotide Delivery Based RNA Editing Technology

Korro Bio shares are trading higher after the company reported better-than-expected Q4 sales results. Also, Raymind James upgraded the stock from Market Perform to Outperform and announced a $23 price target.

Korro Bio shares are trading higher after the company reported better-than-expected Q4 sales results. Also, Raymind James upgraded the stock from Market Perform to Outperform and announced a $23 price target.

Cantor Fitzgerald Maintains Overweight on Korro Bio, Raises Price Target to $22

Raymond James Upgrades Korro Bio to Outperform, Announces $23 Price Target

Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates

Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Korro Bio Q4 EPS $(5.32) Misses $(2.05) Estimate, Sales $1.290M Beat $670.000K Estimate

Korro Announces Oversubscribed $85 Million Private Placement

Korro Bio Secures ~$85M PIPE Financing Via Subscription Agreement

Korro to Present at the TD Cowen 46th Annual Health Care Conference

Clear Street Upgrades Korro Bio to Buy, Raises Price Target to $18

William Blair Upgrades Korro Bio to Outperform